Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Debt Ratio (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Debt Ratio for 9 consecutive years, with 0.09 as the latest value for Q4 2023.

  • For Q4 2023, Debt Ratio fell 13.45% year-over-year to 0.09; the TTM value through Dec 2023 reached 0.09, down 13.45%, while the annual FY2023 figure was 0.09, 13.45% down from the prior year.
  • Debt Ratio hit 0.09 in Q4 2023 for Cartesian Therapeutics, down from 0.17 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.53 in Q3 2019 and bottomed at 0.09 in Q4 2023.
  • Average Debt Ratio over 5 years is 0.2, with a median of 0.16 recorded in 2021.
  • Year-over-year, Debt Ratio surged 58.9% in 2019 and then plummeted 74.33% in 2020.
  • Cartesian Therapeutics' Debt Ratio stood at 0.19 in 2019, then fell by 21.07% to 0.15 in 2020, then rose by 6.98% to 0.16 in 2021, then crashed by 33.13% to 0.11 in 2022, then decreased by 13.45% to 0.09 in 2023.
  • According to Business Quant data, Debt Ratio over the past three periods came in at 0.09, 0.17, and 0.17 for Q4 2023, Q2 2023, and Q1 2023 respectively.